RAPP vs TXT · rev $20.0M vs P/E 19, rev $7.52B
Rapport Therapeutics, Inc. Common Stock (RAPP) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
RAPP currently screens at market cap $532.9M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the RAPP and TXT stock pages for the full models.
Not investment advice.